Sempli Farma

Sempli Farma®, a brand of Remedio Srl, proposes that pharmacies become repackaging centers for sachets ("Personalized Unit Doses") of oral solid drug therapies.

The sachets make it easier and safer for patients to take the right drug, with the right dose, at the right time, thus increasing adherence to therapies, the lack of which touches 50 percent of the 8.8 million poly-treated people in Italy (those who take more than 5 tablets a day), causing morbidity and avoidable costs for the SSN of about 19 billion a year (emergency room accesses, hospitalizations, treatments).

By investing you will become a partner in one of the first movers of a booming market. Sempli Farma®'s service already has 18 repackaging center pharmacies and 43 satellite pharmacies, with more than 2,500 patients served. Revenues for 2022 were € 1.23 mln, with EBITDA 13.1%.

The company's strategic design touches on three points:

1. Build a network of community pharmacies, spread throughout the territory, focused on therapeutic adherence;
2. Carry out an observational study to demonstrate the benefits in terms of therapeutic adherence and thus quality of patient health and reduction of avoidable health care costs, so as to help make the service reimbursed by the SSN;
3. Create a therapeutic adherence marketplace, to sell the service online, including B2C (for this purpose we have already obtained 650k funding, including 180k in grants, from Invitalia).

Specifically, Sempli Farma® provides pharmacies with a sophisticated hardware & software system, which repackages into sachets the medications (tablets or tablets) that the individual patient needs to take at a certain time of the day. The sachets are dispensed either with a simple dispenser, in which the string of sachets (roll) is ordered chronologically, or with a "smart dispenser, " which dispenses the right sachet, already cut, at the predetermined time and reminds the patient, with beeps and lights, that it is time to take it.

Sempli Farma® brings technological, organizational, marketing & sales know-how to pharmacies. It sells repackaging technologies, access to the platform that communicates with prescription and medication management systems (recurrent fees from maintenance, support, consumables and software use licenses). It also receives patient/day fees for Site Management service (which maximizes in-house labor productivity to reduce unit production costs) and Business Development service (marketing activities and patient research for the pharmacy). Other recurrent revenues come from the development of the therapeutic adherence marketplace (platform access and online sales of the Sempli Farma® repackaging service and other related goods and services).

Tax benefits of 30% apply on Sempli Farma.

Sempli Farma reserves the right of "liquidation preference" for all investors participating in the campaign, who will therefore be reimbursed first in the event of an exit than the company's other shareholders (according to the order of preference indicated in the bylaws). All conditions are published in the bylaws found in the Documents section.

On the campaign is available the optional Rubrication free of charge for the Investor as the costs are borne by Sempli Farma.